USD 31.97
(-5.69%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 233.66 Million USD | 8290.02% |
2022 | 2.78 Million USD | -58.36% |
2021 | 6.68 Million USD | 4300.66% |
2020 | 152 Thousand USD | 0.0% |
2019 | 152 Thousand USD | 0.0% |
2018 | 152 Thousand USD | -0.25% |
2017 | 152.38 Thousand USD | 0.0% |
2016 | 152.38 Thousand USD | 0.0% |
2015 | 152.38 Thousand USD | 0.0% |
2014 | 152.38 Thousand USD | 0.0% |
2013 | 152.38 Thousand USD | 699.98% |
2012 | 19.04 Thousand USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | -100.0% |
2002 | 500 Thousand USD | -81.56% |
2001 | 2.71 Million USD | -49.39% |
2000 | 5.35 Million USD | 346.58% |
1999 | 1.2 Million USD | -60.0% |
1998 | 3 Million USD | 2900.0% |
1997 | 100 Thousand USD | 0.0% |
1996 | 100 Thousand USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 63.47 Million USD | 44.35% |
2024 Q2 | 73.46 Million USD | 15.74% |
2024 Q3 | 83.87 Million USD | 14.17% |
2023 Q2 | 16.07 Million USD | 106.0% |
2023 Q4 | 43.97 Million USD | -73.48% |
2023 Q1 | 7.8 Million USD | 9653.75% |
2023 FY | 233.66 Million USD | 8290.02% |
2023 Q3 | 165.81 Million USD | 931.57% |
2022 Q3 | 94 Thousand USD | -84.18% |
2022 Q4 | 80 Thousand USD | -14.89% |
2022 Q2 | 594 Thousand USD | -70.54% |
2022 FY | 2.78 Million USD | -58.36% |
2022 Q1 | 2.01 Million USD | -13.14% |
2021 Q1 | 793 Thousand USD | 1986.84% |
2021 FY | 6.68 Million USD | 4300.66% |
2021 Q2 | 1.54 Million USD | 94.83% |
2021 Q3 | 2.03 Million USD | 31.39% |
2021 Q4 | 2.32 Million USD | 14.33% |
2020 Q4 | 38 Thousand USD | 0.0% |
2020 Q3 | 38 Thousand USD | 0.0% |
2020 Q1 | 38 Thousand USD | 0.0% |
2020 FY | 152 Thousand USD | 0.0% |
2020 Q2 | 38 Thousand USD | 0.0% |
2019 FY | 152 Thousand USD | 0.0% |
2019 Q4 | 38 Thousand USD | 0.0% |
2019 Q1 | 38 Thousand USD | 0.0% |
2019 Q2 | 38 Thousand USD | 0.0% |
2019 Q3 | 38 Thousand USD | 0.0% |
2018 Q3 | 38 Thousand USD | 0.0% |
2018 Q4 | 38 Thousand USD | 0.0% |
2018 FY | 152 Thousand USD | -0.25% |
2018 Q1 | 38 Thousand USD | -0.25% |
2018 Q2 | 38 Thousand USD | 0.0% |
2017 Q3 | 38.09 Thousand USD | 0.0% |
2017 FY | 152.38 Thousand USD | 0.0% |
2017 Q4 | 38.09 Thousand USD | -0.0% |
2017 Q1 | 38.09 Thousand USD | 0.0% |
2017 Q2 | 38.09 Thousand USD | 0.0% |
2016 FY | 152.38 Thousand USD | 0.0% |
2016 Q1 | 38.09 Thousand USD | 0.0% |
2016 Q2 | 38.09 Thousand USD | 0.0% |
2016 Q3 | 38.09 Thousand USD | 0.0% |
2016 Q4 | 38.09 Thousand USD | -0.0% |
2015 Q4 | 38.09 Thousand USD | -0.0% |
2015 Q1 | 38.09 Thousand USD | 0.0% |
2015 Q2 | 38.09 Thousand USD | 0.0% |
2015 Q3 | 38.09 Thousand USD | 0.0% |
2015 FY | 152.38 Thousand USD | 0.0% |
2014 Q4 | 38.09 Thousand USD | -0.0% |
2014 FY | 152.38 Thousand USD | 0.0% |
2014 Q3 | 38.09 Thousand USD | 0.0% |
2014 Q2 | 38.09 Thousand USD | 0.0% |
2014 Q1 | 38.09 Thousand USD | 0.0% |
2013 Q2 | 38.09 Thousand USD | 0.0% |
2013 Q1 | 38.09 Thousand USD | 99.99% |
2013 FY | 152.38 Thousand USD | 699.98% |
2013 Q4 | 38.09 Thousand USD | -0.0% |
2013 Q3 | 38.09 Thousand USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q4 | 19.04 Thousand USD | 0.0% |
2012 FY | 19.04 Thousand USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2007 Q1 | - USD | 100.0% |
2007 Q4 | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 Q4 | -69.81 Thousand USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2005 Q4 | - USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2004 Q3 | - USD | 0.0% |
2004 Q1 | - USD | 0.0% |
2004 Q4 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2004 Q2 | - USD | 0.0% |
2003 FY | - USD | -100.0% |
2003 Q1 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2002 Q3 | - USD | -100.0% |
2002 FY | 500 Thousand USD | -81.56% |
2002 Q4 | - USD | 0.0% |
2002 Q2 | 500 Thousand USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2001 FY | 2.71 Million USD | -49.39% |
2001 Q1 | 2.71 Million USD | 40.8% |
2001 Q2 | 1.00 USD | -100.0% |
2001 Q3 | - USD | -100.0% |
2000 Q3 | 1.07 Million USD | -25.23% |
2000 Q1 | 925.49 Thousand USD | 2.83% |
2000 FY | 5.35 Million USD | 346.58% |
2000 Q2 | 1.43 Million USD | 55.01% |
2000 Q4 | 1.92 Million USD | 79.55% |
1999 FY | 1.2 Million USD | -60.0% |
1999 Q4 | 900 Thousand USD | 200.0% |
1999 Q3 | 300 Thousand USD | 200.0% |
1999 Q2 | 100 Thousand USD | 0.0% |
1999 Q1 | 100 Thousand USD | -80.0% |
1998 FY | 3 Million USD | 2900.0% |
1998 Q2 | 2.5 Million USD | 2400.0% |
1998 Q3 | 100 Thousand USD | -96.0% |
1998 Q4 | 500 Thousand USD | 400.0% |
1998 Q1 | 100 Thousand USD | 0.0% |
1997 Q3 | 100 Thousand USD | 0.0% |
1997 Q4 | - USD | -100.0% |
1997 FY | 100 Thousand USD | 0.0% |
1997 Q1 | 100 Thousand USD | 0.0% |
1997 Q2 | 100 Thousand USD | 0.0% |
1996 Q3 | 100 Thousand USD | 0.0% |
1996 Q4 | - USD | -100.0% |
1996 FY | 100 Thousand USD | 0.0% |
1996 Q1 | 100 Thousand USD | 0.0% |
1996 Q2 | 100 Thousand USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
uniQure N.V. | 15.84 Million USD | -1374.86% |
Abeona Therapeutics Inc. | 3.5 Million USD | -6576.057% |
Aclaris Therapeutics, Inc. | 31.24 Million USD | -647.742% |
Agilent Technologies, Inc. | 6.83 Billion USD | 96.58% |
Agios Pharmaceuticals, Inc. | 26.82 Million USD | -771.126% |
Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 87.22% |
Amicus Therapeutics, Inc. | 399.35 Million USD | 41.49% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Atara Biotherapeutics, Inc. | 8.57 Million USD | -2625.557% |
Axsome Therapeutics, Inc. | 270.6 Million USD | 13.65% |
BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 90.341% |
bluebird bio, Inc. | 29.49 Million USD | -692.155% |
Blueprint Medicines Corporation | 249.38 Million USD | 6.303% |
Cara Therapeutics, Inc. | 20.96 Million USD | -1014.374% |
Imunon, Inc. | - USD | -Infinity% |
Adicet Bio, Inc. | - USD | -Infinity% |
Corcept Therapeutics Incorporated | 482.37 Million USD | 51.56% |
Dynavax Technologies Corporation | 232.28 Million USD | -0.593% |
Editas Medicine, Inc. | 78.12 Million USD | -199.095% |
Emergent BioSolutions Inc. | 1.04 Billion USD | 77.732% |
Esperion Therapeutics, Inc. | 116.33 Million USD | -100.854% |
Exelixis, Inc. | 1.83 Billion USD | 87.233% |
FibroGen, Inc. | 147.75 Million USD | -58.145% |
Geron Corporation | 237 Thousand USD | -98491.561% |
Halozyme Therapeutics, Inc. | 829.25 Million USD | 71.823% |
Heron Therapeutics, Inc. | 127.04 Million USD | -83.922% |
Illumina, Inc. | 4.5 Billion USD | 94.812% |
Incyte Corporation | 3.69 Billion USD | 93.677% |
Insmed Incorporated | 305.2 Million USD | 23.442% |
Intellia Therapeutics, Inc. | 36.27 Million USD | -544.141% |
Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 70.334% |
Iovance Biotherapeutics, Inc. | 1.18 Million USD | -19551.976% |
IQVIA Holdings Inc. | 14.98 Billion USD | 98.441% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 3.78 Billion USD | 93.832% |
Evolus, Inc. | 202.08 Million USD | -15.626% |
Myriad Genetics, Inc. | 678.4 Million USD | 65.557% |
Neurocrine Biosciences, Inc. | 1.88 Billion USD | 87.618% |
OPKO Health, Inc. | 863.49 Million USD | 72.94% |
Sarepta Therapeutics, Inc. | 1.24 Billion USD | 81.207% |
Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 61.538% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.842% |
Waters Corporation | 2.95 Billion USD | 92.096% |
Zoetis Inc. | 8.54 Billion USD | 97.265% |
Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 97.632% |
Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.455% |
Biogen Inc. | 9.83 Billion USD | 97.624% |
Sangamo Therapeutics, Inc. | 176.23 Million USD | -32.588% |
Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 98.219% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Homology Medicines, Inc. | -6.65 Million USD | 3613.186% |
Nektar Therapeutics | 90.12 Million USD | -159.273% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Perrigo Company plc | 4.65 Billion USD | 94.981% |
Unity Biotechnology, Inc. | - USD | -Infinity% |